



## Molecular Mechanism of Amyloid Aggregation

Guest Editor:

**Dr. Siddhartha Banerjee**

Department of Chemistry and  
Biochemistry, University of  
Alabama, Shelby Hall, Room 1009  
Tuscaloosa, AL 35487, USA

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editor

This Special Issue will primarily focus on the molecular mechanism of amyloid aggregation. A tremendous amount of research over the past couple of decades has generated a plethora of information. However, the molecular mechanism that generates aggregates at the initial phase of aggregation is still not understood in detail. Without the in-depth knowledge of these aggregates, which have been identified to be neurotoxic, it is challenging to develop any therapeutics to address the fatal neurodegenerative diseases. Emerging single molecular imaging and spectroscopic biophysical techniques are revealing a new structural and mechanistic understanding of amyloid aggregation that has not been seen previously. We cordially invite authors to submit original research for this Special Issue of *Biomedicines*.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)